The Effects of a Zeaxanthin Intervention on Visuomotor Function

University of Georgia (UGA)

Status

Completed

Conditions

Behavior and Behavior Mechanisms

Treatments

Dietary Supplement: zeaxanthin

Dietary Supplement: combinatory supplement

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT02017418

2012-10531

Details and patient eligibility

About

This study was designed to test whether two zeaxanthin formulations (supplements containing different nutritional compounds with zeaxanthin and omega fatty acids being the primary ingredients of interest) influenced visual motor function. Visual motor function refers to the processing speed of the visual system and how individuals respond behavioral to visual stimuli (e.g., reaction time).

Full description

Enrollment

102 patients

Sex

All

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Age: ≥18 and ≤ 40 years
BMI: ≥ 20 and ≤ 30 kg/m2
No anticipated changes in dieting habits (as relevant to the intake of xanthophylls and fats/oils).
No anticipated surgical procedures.
Willingness and ability to give written informed consent and willingness and ability to comply with the study requirements.
Corrected visual acuity (ETDRS): better than 20/60 in the eye selected for the study

Exclusion criteria

Smokers
Current or history of relevant ocular diseases (such as AMD) or other conditions e.g., lipid disorders.
Inability to reliably perform macular pigment optical density measurements by "Heterochromatic Flicker Photometry" or any of the other ophthalmic tests of the study.
Any condition likely to interfere with normal gastro-intestinal absorption of xanthophylls (e.g., digestive disorders: inflammatory bowel disease, ulcerative colitis, Crohn's, irritable bowel, etc. or lipid disorders including conditions such as hypercholesterolemia)
Current use of xanthophyll containing supplements or use of xanthophyll containing supplements in the past 6 months (but excluding multivitamins containing lutein or zeaxanthin at low potency).
Participation in any other study during last 1 month before study initiation.
Known hypersensitivity or allergy to xanthophylls.
Regular intake of medications or supplements, which the principal investigator deems likely to confound the study outcomes. These include diabetes medication and statins or any other drug/supplement to modulate cholesterol or fat digestion/absorption.